血清纤维化蛋白生物标志物有助于对儿童克罗恩病未来狭窄并发症进行风险分层
该多中心前瞻性观察性起始队列纳入诊断时为炎症表型(B1)的儿童克罗恩病患者116例,比较3年内转为狭窄表型(B2)者58例与维持B1者58例。诊断时血清ECM1上四分位水平与未来纤维狭窄病变相关(HR 3.43,95% CL 1.33,8.42),ASCA IgA(HR 4.99)和CBir(HR 5.19)亦相关。结论认为ECM1等纤维化标志物可能有助于判断B1转为B2的风险,临床实施前需前瞻性验证研究。
要点
- 诊断时血清ECM1上四分位水平与未来纤维狭窄病变相关(HR 3.43,95% CL 1.33,8.42)。
- ASCA IgA(HR 4.99,95% CL 1.50,16.68)和CBir(HR 5.19,95% CL 1.83,14.74)也与未来肠道纤维狭窄相关。
- 多变量分析中校正血清学标志物后ECM1仍与转为B2独立相关(HR 5.33,95% CL 1.29,22.13)。
核心结论
- ECM1及其他纤维化生物标志物可能有助于判断儿童克罗恩病中无并发症的炎症性疾病转为B2狭窄表型的风险。
- 临床实施前需前瞻性验证研究以核实检测性能并优化临床使用。
研究设计与样本
- 利用儿童克罗恩病快速疾病进展免疫遗传与微生物标志物风险分层与识别队列,为多中心前瞻性观察性儿童起始队列。
- 纳入诊断时为炎症表型(B1)且后来3年内转为狭窄表型(B2)的受试者,与维持B1者进行比较。
主要发现
- 116例受试者中,诊断时确认为B1表型且后来转为B2疾病者58例,与3年随访期间维持B1者58例进行比较。
- ECM1上四分位水平与未来纤维狭窄病变相关(HR 3.43,95% CL 1.33,8.42)。
- ASCA IgA(HR 4.99,95% CL 1.50,16.68)和CBir水平(HR 5.19,95% CL 1.83,14.74)也与未来肠道纤维狭窄相关。
- 多变量分析中校正血清学标志物后,ECM1仍显示与转为B2独立相关(HR 5.33,95% CL 1.29,22.13)。
关键数值与推荐
- 诊断时血清经平行反应监测靶向蛋白质组分析和常规酶联免疫吸附试验检测10种候选肠道纤维化生物标志物。
- 采用Cox比例风险回归对时间依赖性结局进行多变量分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出临床实施前需前瞻性验证研究以核实检测性能并优化临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Avoiding fibrostenotic complications is of paramount concern in the management of Crohn's disease (CD). We sought to investigate the association of candidate biomarkers of fibrosis collected at diagnosis with the future development of fibrostenotic CD. METHODS: Using the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease cohort, a multicenter prospective observational pediatric inception cohort, subjects with an inflammatory phenotype (B1) at diagnosis who later converted to a stricturing phenotype (B2) within 3 years were compared with those who remained B1. Serum collected at diagnosis underwent both parallel reaction monitoring-targeted proteomic analysis and conventional enzyme-linked immunosorbent assay for 10 candidate biomarkers of intestinal fibrosis. Cox proportional hazard regression was used for multivariable analysis of time-dependent outcomes. RESULTS: In 116 subjects 58 subjects with verified B1 phenotype at diagnosis who later converted to B2 disease were compared with 58 subjects who remained B1 over 3 years of follow-up. Extracellular matrix protein 1 (ECM1) levels in the upper quartile (hazard ratio [HR] 3.43, 95% confidence limit [CL] 1.33, 8.42) were associated with future fibrostenotic disease. ASCA IgA (HR 4.99, 95% CL 1.50, 16.68) and CBir levels (HR 5.19, 95% CL 1.83, 14.74) were also associated with future intestinal fibrostenosis, although ECM1 continued to demonstrate independent association with conversion to B2 even with adjustment for serologies in multivariable analysis (HR 5.33, 95% CL 1.29, 22.13). CONCLUSIONS: ECM1 and other biomarkers of fibrosis may aid in determining the risk of uncomplicated inflammatory disease converting to B2 stricturing phenotypes in children with CD. Prospective validation studies to verify test performance and optimize clinical utilization are needed before clinical implementation.
引用
- Wu J, Lubman DM, Kugathasan S, et al. Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease. Am J Gastroenterol. 2019. PMID: 31058681. doi:10.14309/ajg.0000000000000237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。